Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.85EUR
11:36am EDT
Price Change (% chg)

€-3.32 (-4.14%)
Prev Close
€80.17
Open
€75.75
Day's High
€77.10
Day's Low
€74.80
Volume
7,272,693
Avg. Vol
2,671,559
52-wk High
€87.03
52-wk Low
€64.20

SASY.PA

Chart for SASY.PA

About

Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company based in France. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs. The Company focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs,... (more)

Overall

Beta: 0.48
Market Cap (Mil.): €107,297.90
Shares Outstanding (Mil.): 1,338.20
Dividend: 2.77
Yield (%): 3.46

Financials

  SASY.PA Industry Sector
P/E (TTM): 25.54 37.93 37.76
EPS (TTM): 3.14 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

Sanofi cuts 2013 goal, authorities visit China office

PARIS - Sanofi SA cut its 2013 earnings forecast as it reported a steeper-than-expected drop in second-quarter profit, hit by the effect of patent losses, currency fluctuations and an inventory setback in Brazil.

5:00am EDT

UPDATE 2-Sanofi cuts 2013 goal, authorities visit China office

* Shares down 6.2 percent (Adds details, CEO comments, background)

4:58am EDT

BRIEF-Sanofi opens 5.8 pct lower on Q2, 2013 target cut

PARIS, Aug 1 - Sanofi SA : * opens 5.8 percent lower on Q2 earnings miss, 2013 target cut, China probe

3:02am EDT

Sanofi CEO says authorities visit China office

PARIS - Sanofi said one of its regional offices in China has been visited by the State Administration for Industry and Commerce in Shenyang as part of a probe into a bribery scandal that has involved other Western drugmakers.

2:18am EDT

Sanofi CEO says authorities visit China office

PARIS, Aug 1 - Sanofi said one of its regional offices in China has been visited by the State Administration for Industry and Commerce in Shenyang as part of a probe into a bribery scandal that has involved other Western drugmakers.

2:14am EDT

FDA panel recommends over-the-counter use of Sanofi allergy drug

WASHINGTON - Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, a panel of advisors to the U.S. Food and Drug Administration ruled on Wednesday.

31 Jul 2013

FDA panel recommends over-the-counter use of Sanofi allergy drug

WASHINGTON, July 31 - Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, a panel of advisors to the U.S. Food and Drug Administration ruled on Wednesday.

31 Jul 2013

UPDATE 1-Sanofi allergy drug safe for non-prescription use-FDA reviewers

WASHINGTON, July 29 - Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, according to reviewers for the U.S. Food and Drug Administration.

29 Jul 2013

Sanofi allergy drug safe enough for non-prescription use -FDA reviewers

WASHINGTON, July 29 - Sanofi SA's allergy drug Nasacort AQ is safe enough to be sold over the counter, according to reviewers for the U.S. Food and Drug Administration.

29 Jul 2013

Sanofi, Carlyle in talks to buy Elder Pharma's India formulations business-sources

July 24 - Sanofi SA's India unit and Carlyle Group are in separate talks to buy the domestic drug formulations business of India's Elder Pharmaceuticals Ltd for $400 million-$450 million, three sources with direct knowledge of the matter said.

24 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: Finlabo SIM Spa
$10.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks